Alzheimer's Disease | Landscape & Forecast | Disease Landscape & Forecast

Publish date: June 2019

Login to access report

The Alzheimer’s disease (AD) market today comprises a handful of symptomatic options that offer only modest efficacy of limited duration, leaving ample room for novel, more-effective alternatives—in particular, disease-modifying therapies capable of slowing disease progression. As the baby boomer generation ages, we forecast a rapidly growing pool of patients suffering from this devastating condition, a trend that will simultaneously increase the treatment-eligible patient pool and impose a new strain on healthcare resources. Considering the huge unmet need, many drug developers continue to invest heavily in this space, despite a perennially high rate of attrition. The launch of potential disease-modifying therapies (DMTs)—e.g., those targeting the amyloid cascade—would dramatically expand the market for AD therapies, but current launch prospects are low. The launch of two behavioral therapies for the treatment of agitation associated with AD, a burdensome symptom affecting both patients and caregivers, is more likely but still uncertain. Ultimately, we expect investigational products will only partially fulfill the need for therapeutic advances should they launch.


  • How large is the treatable AD population, and how will diagnosis/drug-treatment rates change over time? What will the impact of DMTs be on diagnosis/drug treatment and in which populations?
  • What pipeline products are the most promising, and what sales/uptake could they secure in AD? What is the forecast for emerging DMTs or agents to treat agitation in AD such as Avanir/Otsuka’s AVP-786?
  • What are the drivers and constraints in the AD therapy market, and how might they change over the forecast period as premium-priced agents enter the market?


Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • June 2019
      • March 2019
      • December 2018
      • September 2018
      • June 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Alzheimer's Disease?
        • What Factors Are Constraining the Market for Alzheimer's Disease?
      • Drug-Class-Specific Trends
        • Acetylcholinesterase Inhibitors
        • NMDA Receptor Antagonists
        • Donepezil/Memantine Fixed-Dose Combinations
        • Behavioral Therapies
      • Alternative Market Scenarios
        • Disease-Modifying Therapies
        • Behavioural Therapies
    • Forecast
      • Market Forecast Assumptions
      • Market-Forecast-Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Etiology
      • Pathophysiology
      • Disease Progression/Natural History
      • Key Pathways and Drug Targets
        • Key Drug Targets
    • Epidemiology Overview
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of AD
        • Total Prevalent Cases of AD by Severity
        • Total Ten-Year Prevalent Cases of Pre-AD
        • Diagnosed Prevalent Cases of AD by Symptom Status
        • Diagnosed Prevalent Cases of Symptomatic Pre-AD and AD by Severity
        • Drug-Treated Cases of Symptomatic Pre-AD and AD by Severity
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview of Alzheimer's Disease Drug Classification
        • Acetylcholinesterase Inhibitors
        • NMDA Receptor Antagonists
        • Antipsychotics
        • Antidepressants
      • Medical Practice
        • Overview
        • Current Diagnostics
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Alzheimer's Disease
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Alzheimer's Disease
        • Drug Development and Regulatory Hurdles
        • Disease-Modifying Therapies
        • NMDA Receptor Modulators
        • Antipsychotics
        • Other Notable Mid- and Late-Phase Compounds in Development for Alzheimer's Disease
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Alzheimer's Disease
      • Prominent Late Phase Failures in AD
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Alzheimer's Disease Bibliography

Author(s): Ruchita Kumar, Ph.D; Jonathan Searles; Fjoralba Kristo, MD, MPH

Ruchita has joined as a Lead Analyst in the Central Nervous System and Ophthalmology team at Decision Resources Group. She comes with eight years of experience in handling various types of commercial assessment projects. She has worked on variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, epi-based forecasts, patent landscapes, social media analysis and building brand performance reports across different therapy areas. She earned a in design and development of modified release dosage forms of anti-diabetic drugs from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh.

Jonathan ;Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, ;Searles received a degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.

Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods. Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.